Idex Corporation Lifts 2026 Outlook After Strong Q1

Idex Corporation ((IEX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Idex Corporation’s latest earnings call carried a clearly positive tone as management unveiled stronger-than-expected Q1 results and raised full-year guidance. Executives emphasized robust momentum in Health & Science Technologies, expanding margins, and a growing backlog that supports confidence in a multi-year growth runway, while acknowledging pockets of softness in certain industrial and life sciences end markets.

Upgraded 2026 Organic Growth Outlook

Idex lifted its full-year 2026 organic growth outlook to 3%–4%, up from the prior 1%–2% range. Management tied the upgrade to stronger-than-anticipated demand, particularly in its higher-growth platforms, underscoring increased conviction that the current cycle has more room to run.

Q1 Sales and Orders Beat Expectations

First-quarter organic sales rose 5%, while consolidated organic orders climbed about 10% year over year, both ahead of internal expectations. The strong order intake sets a supportive base for the remainder of 2026, signaling that customer demand is holding up despite broader macro uncertainty.

HST Segment Powers Growth

Health & Science Technologies was the standout performer with organic orders up 17% and organic revenue up 11% in Q1. Segment adjusted EBITDA margin expanded by roughly 100 basis points, helped by secular demand from data centers, semiconductors, space and defense, and pharmaceutical customers.

Margin Expansion at the Consolidated Level

Idex delivered an adjusted EBITDA margin of 26% in the quarter, a 50 basis-point improvement versus last year. Management credited productivity measures, volume leverage, and disciplined price/cost management, reinforcing the company’s ability to expand profitability even as mix presents some headwinds.

Backlog Build Enhances Visibility

A notable backlog build in HST has improved visibility into the rest of 2026 and even into 2027. This backlog strength underpins management’s confidence in a durable multi-year growth trajectory and supports the decision to upgrade full-year targets.

Strong Capital Allocation and Liquidity

The company repurchased $76 million of shares in Q1 and intends to maintain that quarterly pace through 2026, while also paying $53 million in dividends. Idex closed the quarter with about $1.1 billion in liquidity and gross leverage near 2x, providing ample flexibility for both shareholder returns and strategic investments.

EPS Guidance Moved Higher

Management raised 2026 adjusted EPS guidance by $0.20 to a range of $8.35–$8.55, implying mid- to high-single-digit growth versus last year. For Q2, Idex projected adjusted EPS between $2.07 and $2.12, in line with the upgraded full-year trajectory.

Active Bolt-On M&A Strategy

Idex highlighted an active pipeline for bolt-on acquisitions that complement its existing businesses and support long-term growth. Recent acquisitions are already contributing to revenue, even though their current margins sit below segment averages and present an opportunity for future improvement.

Pressure in FSDP and Short-Cycle Industrials

Within the Fluid & Metering–adjacent Fire, Safety and Diversified Products area, organic orders fell 4% and sales slipped 1% in Q1. Weakness in the dispensing business, driven by tough comparisons and softer project volumes in North America and Asia, offset high single-digit growth in Fire & Safety and a patchy recovery in short-cycle industrial diagnostics.

Mixed Dynamics in FMT Segment

The Fluid & Metering Technologies segment posted a 9% increase in orders but only 2% organic sales growth in Q1. Adjusted EBITDA margin dipped about 10 basis points year over year, as unfavorable mix and volume deleverage weighed on results, with softness in chemical markets partly balancing solid performance in water and pump applications.

Life Sciences Under Pressure

Within HST, life sciences saw muted, low single-digit growth as demand from China weakened and academic and government-related funding remained constrained. This pressure also diluted the segment’s higher-margin mix, tempering what otherwise would have been even stronger profitability.

Gross Margin and Cash Flow Headwinds

Adjusted gross margin slipped around 40 basis points to 44.9% as productivity and volume gains were more than offset by unfavorable mix. Free cash flow of $86 million in Q1 was down $5 million versus last year, reflecting higher working capital tied to growth in what is typically the company’s weakest cash quarter.

Incremental Margins and Mix in HST

HST incremental flow-through has recently run in the low-to-mid 30% range, with management targeting the mid-30s for 2026 and aiming for about 40% over time. The current drag stems from acquired businesses that carry below-average margins and from mix shifts, prompting ongoing 80/20 initiatives to sharpen focus on higher-return products and customers.

Upbeat but Balanced Forward Guidance

Looking ahead, Idex now forecasts 3%–4% organic growth for 2026, with HST expected to grow at a high-single-digit pace while FMT and FSDP remain roughly flat. The company kept its adjusted EBITDA margin guidance at 26.5%–27.0% and lifted adjusted EPS to $8.35–$8.55, with Q2 expected to deliver 3%–4% organic growth, similar margins, and adjusted EPS of $2.07–$2.12.

Idex’s earnings call painted a picture of a company leaning into its strongest platforms while managing through pockets of softness. With upgraded growth and EPS guidance, expanding margins, disciplined capital deployment, and a healthy backlog, the story remains skewed positively for investors, even as mix, life sciences, and select industrial exposures demand ongoing vigilance.